Alexion Pharmaceuticals Profile

<div class='logoBackup' style='background:#0D8ECF;color: white;font-size:3em;;'>ALX</div>


6 / 100

Odds of Distress

Analyze Filter   Earning Report: February 3, 2020
Equity ratings for Alexion Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting October 21, 2019 and ending today January 19, 2020. Click here to learn more.

Alexion Pharmaceuticals Profile

Upcoming quarterly earning report is expected on February 3, 2020. Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Alexion Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2656 people. more on Alexion Pharmaceuticals
Alexion Pharmaceuticals Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Alexion Pharmaceuticals SEC Filings
Alexion Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAlexion Pharmaceuticals
CEO, DirectorLudwig HantsonView All
Thematic Classification
Currently Active Investing Idea
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
RegionNorth America
LocationMassachusetts; U.S.A
Business Address121 Seaport Boulevard, Boston, MA 02210, United States
Cash and Equivalents
Healthcare, Biotechnology
InstrumentUSA Stock View All
Net Income
Foreign Associates
ExchangeBATS Exchange
CIK Number0000899866
Net Cash Flow from Operations
Phone475 230 2596
CurrencyUSD - US Dollar
Alexion Pharmaceuticals (ALXN) is traded on BATS Exchange in USA. It is located in 121 Seaport Boulevard, Boston, MA 02210, United States and employs 2,656 people. Alexion Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 23.46 B. Alexion Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 224.23 M outstanding shares of which 4.66 M shares are presently shorted by private and institutional investors with about 2.43 trading days to cover. ALEXION PHARM INC currently holds about 2.1 B in cash with 1.44 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.34.
Check Alexion Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Alexion Pharmaceuticals Target Price Odds Analysis

Odds Below 113.27HorizonTargetOdds Above 113.27
87.51%30 days 113.27 12.32%
Based on normal probability distribution, the odds of Alexion Pharmaceuticals to move above current price in 30 days from now is about 12.32 (This Alexion Pharmaceuticals probability density function shows the probability of Alexion Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Alexion Pharmaceuticals Top Holders

Alexion Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Centre Asset Management LlcCommon Shares80.6 K8.7 M
United Services Automobile AssociationCommon Shares49.3 K5.4 M
Xr Securities LlcCall Options10.7 K27 K
View Alexion Pharmaceuticals Diagnostics

Alexion Pharmaceuticals Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Alexion Pharmaceuticals Key Fundamentals

Alexion Pharmaceuticals Against Markets

Did you try this?

Run Equity Valuation Now


Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Alexion Pharmaceuticals Upcoming and Recent Events

Alexion Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 3, 2020
Next Earnings ReportApril 23, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 3, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Alexion Pharmaceuticals Corporate Filings

Alexion Pharmaceuticals SEC Reporting

Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
Unclassified Corporate Event
Results of Operations and Financial Condition
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Alexion Pharmaceuticals Corporate Directors

Felix Baker Director
Andreas Rummelt Independent Director
Deborah Dunsire Independent Director
Please continue to Trending Equities. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Company logos by clearbit